Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab

Patricia Muñoz-Villegas,1 Alejandra Sanchez-Rios,1 Mayra G Quinonez-Alvarado,2 Oscar Olvera-Montaño,1 Juan D Quintana-Hau,2 Leopoldo Baiza-Duran1 1Medical Affairs Department, Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, México; 2Research and Development Depar...

Full description

Bibliographic Details
Main Authors:	Muñoz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado MG, Olvera-Montaño O, Quintana-Hau JD, Baiza-Duran L
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-05-01
Series:	Journal of Experimental Pharmacology
Subjects:	bevacizumab pharmacokinetics ranibizumab safety vascular endothelial growth factor
Online Access:	https://www.dovepress.com/pharmacokinetics-and-safety-of-an-intravitreal-humanized-anti-vegf-a-m-peer-reviewed-fulltext-article-JEP

Similar Items

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
by: Jay U Sheth, et al.
Published: (2021-01-01)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
by: Kiss S, et al.
Published: (2018-08-01)

Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021-01-01)

The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs
by: Berker Bakbak, et al.
Published: (2016-01-01)

Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina
by: Svjetlana Terzić, et al.
Published: (2015-08-01)

Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep
by: Tugba Cakmak Argun, et al.
Published: (2017-07-01)

A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
by: Suthasinee Kumluang, et al.
Published: (2019-03-01)

Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
by: Aysegül Tura, et al.
Published: (2019-06-01)

Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
by: Xiao-Yu Zhang, et al.
Published: (2014-04-01)

Comparison of Corneal Endothelial Changes After a Single-Dose Injection of Bevacizumab or Ranibizumab
by: Fatih Horozoğlu, et al.
Published: (2013-12-01)

Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: A retrospective review
by: Francis Char DeCroos, et al.
Published: (2014-01-01)

Inflammatory Complications of Intravitreal Anti-VEGF Injections
by: Jacob T. Cox, et al.
Published: (2021-03-01)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019-07-01)

Immediate sequential bilateral intravitreal injections: an Indian perspective
by: Tripathy K
Published: (2017-04-01)

Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
by: Alex Yuan, et al.
Published: (2014-02-01)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
by: Tariq Al-Debasi, et al.
Published: (2017-04-01)

Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizuma
by: Kanwal Zareen Abbasi
Published: (2016-03-01)

Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments
by: Anna-Kaisa Rimpelä, et al.
Published: (2018-12-01)

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model
by: Cem Küçükerdönmez, et al.
Published: (2013-04-01)

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema
by: Joel Hanhart, et al.
Published: (2015-02-01)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
by: Lin CJ, et al.
Published: (2016-07-01)

Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration
by: Renata Portella Nunes, et al.
Published: (2019-02-01)

Review of effects of anti-VEGF treatment on refractive error
by: Mintz-Hittner HA, et al.
Published: (2016-06-01)

Estudio de utilización de medicamentos biológicos ranibizumab y bevacizumab en el servicio de oftalmología del hospital nacional Edgardo Rebagliati Martins de mayo 2011 a mayo 2012
by: Armas Loarte, Guido Simón
Published: (2015)

Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure:a comparative clinical study
by: Gökhan Özge, et al.
Published: (2013-04-01)

Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis
by: Shi-Dan Wang, et al.
Published: (2020-05-01)

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations
by: Bianka Sobolewska, et al.
Published: (2017-06-01)

Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema
by: Sever Ozkan, et al.
Published: (2019-01-01)

Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use
by: Ramy M. Hanna, et al.
Published: (2020-10-01)

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
by: Zhuo Ye, et al.
Published: (2015-08-01)

ANGIOGENESIS IN PROLIFERATIVE DIABETIC RETINOPATHY: RERSPECTIVES OF ANTI-VEGF THERAPY (REVIEW OF LITERATURE)
by: V. I. Konenkov, et al.
Published: (2015-12-01)

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016-08-01)

Book Review: Anti-VEGF Use in Ophthalmology
by: Robin A. Vora
Published: (2017-09-01)

The Effect of Intravitreal Bevacizumab on Apoptosis of Rat Retina Cells
by: Özcan Kayıkçıoğlu, et al.
Published: (2013-01-01)

Intravitreal Bevacizumab in Vitreous Hemorrhage and Diabetes Mellitus
by: Beuy Joob, et al.
Published: (2017-03-01)

Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
by: Wen-Jie Wang, et al.
Published: (2015-02-01)

Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model
by: Olvera-Montaño O, et al.
Published: (2019-11-01)

6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome
by: Patrick J Chiam, et al.
Published: (2016-04-01)

Cannot write session to /tmp/vufind_sessions/sess_e8buoqm98hvne5h32vv0rhk3kj